Long-acting, subcutaneously administered, PYY RA are undergoing early phase clinical trials as obesity treatments either alone or in combination with GLP-1 RA (Table 1, NCT02568306 and NCT03574584)
The combination of metabolic and central nervous system effects may provide better tools for maintaining reduced body weight over extended periods
These pharmacies prepare medications according to individualized prescriptions when a licensed provider determines its clinically appropriate for a specific patient
Even measured on the same kind of DEXA scan that started the alarm, the share of weight that comes off as lean mass on a GLP-1 is ordinary
Fortunately, theyre also treatable
Given the multiple pathophysiologic targets that exist in the setting of T2DM, it is common to encounter patients who require the use of multiple antihyperglycemic agents to successfully reach treatment goals